Clinical trials: Antiviral Treatment
Hepatitis C, Depression
Hepatitis C Translating Initiatives for Depression Into Effective Solutions
Chronic infection with hepatitis C (CHC) is a common and expensive condition, and it disproportionately affects Veterans. Treatment with antiviral therapy reduces liver disease progression and improves health related quality of…
- Trial name
- HEPTIDES (NCT01143896)
- Testing
- Depression collaborative care model
- Where
- 4 sites in United States
- Volunteers
- 309 people
- Sponsor
- VA Office of Research and Development
Human Immunodeficiency Virus, Ischemic Heart Disease
Omacor and Cardiovascular Risk Factors in HIV Patients on HAART Treatment
The purpose of this study is to evaluate the effect of Omacor 4g/day on blood lipid parameters and on the function and stiffness of blood vessels in HIV infected patients on Antiretroviral Therapy (HAART)
- Trial name
- NCT00296153
- Testing
- Omega-3-acid ethyl esters 90
- Where
- Denmark
- Volunteers
- 51 people
- Sponsor
- Pronova BioPharma
HIV -1 Infection
Early Neutralizing Antibodies in Infants Living With HIV to Enhance Their Life (2)
The goal of this clinical trial is to learn if subcutaneous ePGT121v1-LS and VRC07-523-LS added to standard antiretroviral therapy (ART) is safe and helps improve HIV viral suppression in infants living with HIV in Mozambique and…
- Trial name
- ENABLE 2 (NCT07655141)
- Testing
- Broadly neutralizing antibody (bNAb) ePGT121v1-LS, Saline (0.9% NaCl), Broadly neutralizing antibody (bNAb) VRC07-523-LS
- Volunteers
- 73 people
- Sponsor
- Hospital Universitario 12 de Octubre
HIV Infections
Evaluating the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody (VRC01) in HIV-Infected Adults Undergoing a Brief Treatment Interruption
The purpose of this study was to evaluate the safety, tolerability, pharmacokinetics (PK), and antiviral activity of an antibody (called VRC01) in HIV-infected adults whose HIV was well-controlled with HIV medicines.
- Trial name
- NCT02463227
- Testing
- VRC01
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cirrhosis, Liver
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
The purpose of this study is to examine the safety and effectiveness of GI262570 compared to placebo (a pill that looks exactly like GI262570 but contains no active medicine) in improving specific tests that indicate the degree…
- Trial name
- NCT00244751
- Testing
- GI262570 0.5 mg, GI262570 1.0 mg
- Where
- 121 sites in United States, Australia and 12 more
- Volunteers
- 265 people
- Sponsor
- GlaxoSmithKline
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19)
A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19
A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People with Weakened Immune Systems or at Increased Risk for Poor Outcomes who are Hospitalized Due to Severe COVID-19
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19), Immunocompromised, Hospitalization
- Trial name
- EPIC-HOS (NCT05545319)
- Testing
- Nirmatrelvir, Ritonavir
- Where
- 11 sites in United States, Bulgaria
- Sponsor
- Pfizer
HIV-1 Infection, HCV Infection
Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment
This study will evaluate efficacy of ledipasvir/sofosbuvir (LDV/SOF) and safety and tolerability of switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) or emtricitabine/rilpivirine/tenofovir…
- Trial name
- Co-STARs (NCT02707601)
- Testing
- E/C/F/TAF, F/R/TAF, LDV/SOF
- Where
- 43 sites in United States, Puerto Rico
- Volunteers
- 150 people
- Sponsor
- Gilead Sciences
Hepatitis C
Multiple Ascending Dose Study of Miravirsen in Treatment-Naïve Chronic Hepatitis C Subjects
The main purpose of this study is to determine the safety and tolerability of multiple dosing of miravirsen in subjects infected with chronic hepatitis C.
- Trial name
- NCT01200420
- Testing
- miravirsen, saline
- Where
- 7 sites in United States, Germany and 4 more
- Volunteers
- 38 people
- Sponsor
- Santaris Pharma A/S
HIV
Toll-like Receptor 9 Agonist Treatment in Chronic HIV-1 Infection
Combination antiretroviral treatment (cART) effectively suppresses virus replication and partially restores immune functions. However, cART cannot cure HIV infection.
- Trial name
- TEACH (NCT02443935)
- Testing
- MGN1703
- Where
- 2 sites in Denmark
- Volunteers
- 12 people
- Sponsor
- University of Aarhus
Chronic Hepatitis C, Fibrosis
Combination Drug Therapy for Patients With Hepatitis C
Hepatitis C is a major cause of liver disease in the United States and leads to cirrhosis of the liver in approximately one-third of patients some of whom will ultimately suffer from liver failure or liver cancer.
- Conditions
- Chronic Hepatitis C, Fibrosis, Hemolytic Anemia
- Trial name
- NCT00001729
- Testing
- Ribavirin
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Patients With Malignant Blood Disease Requiring Hepatitis B Antiviral Medication
Clinical Trial for Non-inferiority and Safety of Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate in Patients With Hematologic Malignancies Who Require Prophylactic Hepatitis B Antiviral Treatment
his clinical trial was conducted to determine the non-inferiority and safety of prophylactic antiviral treatment of Tenofovir alafenamide (TAF) compared to Tenofovir disoproxil fumarate (TDF) in patients with malignant…
- Trial name
- NCT06221657
- Testing
- Vemlidy, Virreal
- Volunteers
- 100 people
- Sponsor
- Yonsei University
Cytomegalovirus Retinitis, HIV Infections
A Study of Foscarnet in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS Who Have Not Had Success With Ganciclovir
To evaluate the safety and efficacy of foscarnet induction treatment of cytomegalovirus (CMV) retinitis in AIDS patients who have previously suffered severe dose-limiting ganciclovir-related myelosuppression, who are ineligible…
- Trial name
- NCT00002301
- Testing
- Foscarnet sodium
- Where
- United States
- Sponsor
- Astra USA
Chronic Hepatitis C
"Real Life" Evaluation of Efficacy and Safety of Direct Antiviral Agents (DAAs) for the Treatment of Hepatitis C Virus in Egypt
The primary purpose of the ANRS 12332 HepNile study cohort is to assess in "Real-Life" condition the efficacy and the safety profile of new Direct Acting Antivirals (DAAs) introduced in the Egyptian National Treatment Programme…
- Trial name
- HepNile (NCT03510637)
- Where
- 3 sites in Egypt
- Volunteers
- 7,500 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HBV, HCC
Predictive Value of HBV pgRNA on Long-term Outcomes in Hepatitis B Patients Treated With Antiviral Therapy
The goal of this prospective, exploratory, non-intervention, multi-center, real-world study is to investigate the predictive value of HBV pgRNA in the occurrence of long-term outcomes under antiviral therapy in patients with…
- Trial name
- NCT05965388
- Testing
- nucleoside analogues or interferon
- Where
- 10 sites in China
- Volunteers
- 5,000 people
- Sponsor
- Wen-hong Zhang
HIV Associated HCV
Analysis of the Impact of HCV Treatment by Last Generation Direct Antiviral Agents (DAA) on Antiviral Immunity and HIV DNA Reservoir in Coinfected HIV-HCV Patients
Spontaneous recovery of patients infected with HCV is related to the development of a cytotoxic immune response that is executed by specialized white blood cells, the CD8+ T cells, which develop a virus-specific response.
- Trial name
- HCURE (NCT03244371)
- Testing
- blood draw
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
HIV Infections, Tuberculosis
A Study to Determine the Best Dose of Antivirals in Patients With Both TB and HIV
Because drugs used to treat TB can reduce the amount of the anti-HIV drugs that reach the sites where the virus is located, this study is designed to see whether it is necessary to use higher doses of antiviral (anti-HIV) drugs…
- Trial name
- OPTI-NNRTI (NCT00523458)
- Testing
- efavirenz or nevirapine
- Where
- Brazil
- Volunteers
- 5 people
- Sponsor
- Stanford University
HIV Infections
A Phase I Study to Evaluate the Pharmacokinetics, Safety and Antiviral Effects of Concurrent Administration of Zidovudine (AZT) and 2'3'-Dideoxyinosine (ddI) in Patients With Human Immunodeficiency Virus (HIV)
To determine the safety and tolerance of various combinations of zidovudine (AZT) and didanosine (ddI) administered concurrently. To determine the pharmacokinetics of concurrent AZT and ddI administered orally.
- Trial name
- NCT00002014
- Testing
- Zidovudine, Didanosine
- Where
- 4 sites in United States
- Sponsor
- Glaxo Wellcome
COVID-19 Respiratory Infection, SARS-CoV2 Infection
Echinaforce COVID-19 Shedding Study
Respiratory viruses pose a permanent threat to humans and society as demonstrated by the current Covid-19 pandemic. Novel drugs and vaccines provide a means for controlling illness.
- Trial name
- NCT04999098
- Testing
- Echinaforce Forte tablets, Echinaforce Chewable tablets, Echinaforce tincture
- Where
- Bulgaria
- Volunteers
- 40 people
- Sponsor
- A. Vogel AG
Hepatitis C
A Study Evaluating the Safety and Clinical Activity of HCV-796 in Treatment-Naive and Non-Responder Subjects
This is a phase 2, randomized, open-label study comparing the safety, antiviral activity, and pharmacokinetics of HCV-796 administered in combination with peginterferon alfa 2B (Peg-Intron) plus concomitant Rebetol vs.
- Trial name
- NCT00367887
- Testing
- Peg-Intron, REBETOL, HCV 796
- Where
- 35 sites in United States, Puerto Rico
- Volunteers
- 246 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Gastric Cancer
Pilot Study of Antiviral Treatment in Combination With Low-dose Gemcitabine in EBV-associated Gastric Cancer (EBVaGC)
Epstein-Barr virus (EBV) is a double-stranded DNA human gamma herpes virus that establishes a persistent infection in over 90% of individuals.
- Trial name
- NCT05431244
- Testing
- Antiviral treatment in combination with low-dose gemcitabine
- Where
- South Korea
- Sponsor
- Samsung Medical Center